Ariad Pharmaceuticals (ARIA) Moves Higher after FDA Node for Iclusig
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Cuts PT on ARIAD Pharma (ARIA) Due to Iclusig Safety Issues, Maintains Buy
December 17, 2012 7:56 AM ESTOn Friday ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib). Despite the good news, analysts at Jefferies lowered their price target on ARIAD Pharma to $23 from $27, though they maintained a Buy rating. The price cut relates to new... More
